SEATTLE, Oct. 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings with investors at the Wells Fargo 2023 Virtual Private Biotech Symposium on Wednesday, November 1, 2023 and at the Piper Sandler 35th Annual Healthcare Conference from November 28 – November 30, 2023..

西雅图，2023年10月24日/PRNewswire/-ProfoundBio，一家专注于开发新型癌症抗体-药物偶联疗法的临床阶段生物技术公司，宣布管理层将参加与投资者的一对一会议。Wells-Fargo 2023虚拟私营生物技术研讨会于11月1日星期三举行，2023年11月28日至2023年11月30日在Piper Sandler第35届年度医疗会议上。。

'We look forward to participating in these conferences to discuss our emerging clinical data from SITC and company growth plans with investors' said Baiteng Zhao, PhD, CEO of ProfoundBio. 'This is an exciting time for ProfoundBio as we explore the potential for our innovative ADC technology platform in the clinical setting.'.

“我们期待参加这些会议，与投资者讨论来自SITC和公司成长计划的新兴临床数据，ProfoundBio首席执行官赵博士说。”对于ProfoundBio来说，这是一个激动人心的时刻，因为我们探索了我们创新的ADC技术平台在临床环境中的潜力。

About ProfoundBio

关于ProfoundBio

ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.

ProfoundBio是一家临床阶段的生物技术公司，专注于开发具有癌症患者治愈潜力的新型抗体治疗药物。ProfoundBio建立在内部开发，创新和专有技术平台的基础上，开发了一个由多种抗体-药物偶联物（ADC）候选药物组成的管道，这些候选药物针对发现，临床前和临床开发阶段的实体瘤和血液恶性肿瘤。

The company's clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA..

该公司的临床阶段计划是rinatabart sesutecan（Rina-s；PRO1184），一种靶向叶酸受体α的ADC，PRO1160，一种靶向CD70的ADC，以及PRO1107，一种靶向PTK7的ADC。ProfoundBio总部设在美国华盛顿州西雅图。。

For more information, please visit www.profoundbio.com.

欲了解更多信息，请访问www.profoundbio.com。

SOURCE ProfoundBio

来源ProfoundBio